ChartMill · Aug 22, 2026
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals
Exelixis (EXEL) passes Decent Value screen: strong valuation, top profitability, no debt, and solid growth. A quality value stock in biotech.
EX
NASDAQ · EXEL
Exelixis, Inc.
Healthcare · Biotechnology
$54.45
Down-$0.81 (-1.47%)
Updated Aug 31, 2026, 12:52 PM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 11.1B
- P/E ratio
- 16.39
- Dividend yield
- 0.00%
- 52-week range
- $33.76 – $57.57
- Volume
- 1.49M
- Avg. volume
- 2.76M
Price performance
EXEL price history
1M range · 0 trading sessions · Daily adjusted prices
EXEL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest EXEL news
The latest Smart Investors Daily articles mentioning EXEL.
Stock researchCompany · Overview
EXEL research
Overview
Company profile and research snapshot.
Company profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $43.82
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Market Perform | — |
| Aug 6, 2026 | Truist Securities | Hold | — |
| Aug 6, 2026 | Stifel | Hold | — |
| Jul 23, 2026 | Morgan Stanley | Equal-Weight | — |
| Jul 14, 2026 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 22, 2026
Exelixis, Valaris, and 3 More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
SeekingAlpha · Aug 21, 2026
Tracking Renaissance Technologies (RenTec) 13F Portfolio - Q2 2026 Update
RenTecâs Q2 2026 13F: NVDA is top holding; big buys in GOOGL, META, TSLA & TSM, trims in AAPL & INTC. Read here for more details.
Benzinga · Aug 19, 2026
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54
BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and announces Price Target of $54.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
